Results of the CAPRISA 012c clinical trial of a combination of two bnAbs to prevent HIV infection in young women in southern Africa announced at AIDS 2026
Researchers at the AIDS 2026 conference announced results from a Phase II clinical trial of long-acting broadly neutralizing antibodies (bnAbs) for HIV prevention. The study specifically targets young women aged 15-24 in sub-Saharan Africa.
Why it matters
This trial represents a potential breakthrough in medical interventions to reduce HIV transmission rates among high-risk demographics.
Young women 15-24 years in sub-Saharan African continue to bear the brunt of the HIV epidemic. Researchers from the Centre for the AIDS Programme of Research in South Africa (CAPRISA) announced the results of a Phase II clinical trial evaluating long-acting broadly neutralising antibodies (bnAbs) for preventing HIV infection in young women at AIDS 2026.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in